Catalent Affirms Commitment to Customers and Patients Amidst Novo Holdings Acquisition
Alessandro Maselli to Remain President and CEO of Catalent Post-Acquisition
Catalent, Inc. (NYSE: CTLT), a leader in the development and supply of innovative treatments for patients worldwide, has released an open letter to its customers addressing the pending acquisition by Novo Holdings.
To Our Valued Customers,
I want to address some inaccuracies reported in the press regarding Novo Holdings’ upcoming acquisition of Catalent and reaffirm our commitment to our mission: to develop, manufacture, and supply products that enhance health and well-being.
Novo Holdings is a global life science investment firm focused on creating long-term, sustainable value. After the completion of the acquisition, Catalent will operate as a private company under Novo Holdings’ ownership, maintaining its position as a leading global, independent, full-service contract development and manufacturing organization (CDMO). Our nearly 50 global sites will continue to:
- Provide cutting-edge technology, scalable capacity, and proven regulatory expertise, all backed by our commitment to excellence.
- Collaborate closely with you to guide your products through development and clinical trials, ensuring reliable supply for commercial launches and beyond.
- Offer fill and finish services for sterile products, including gene and cell therapies, in which we are actively investing and expanding.
- Work diligently to increase patient access to essential treatments and cures.
I am pleased to announce that I will continue to lead Catalent as President and CEO following the acquisition. My decision to remain in this role is bolstered by Novo Holdings’ commitment to providing the necessary support and capital to enhance our services and create new jobs as we pursue growth at Catalent. I look forward to partnering with our dedicated employees and Novo Holdings in this exciting new chapter.
Since the announcement of this acquisition, our focus at Catalent has remained steadfast on ensuring a reliable, high-quality supply of products for patients in need. We are proud to report continued strong levels of new business wins across our services, and we deeply appreciate the trust you place in us.
I want to emphasize that our commitments to you will not change. Your products will continue to be our top priority, and we will protect your proprietary information.
As we move forward, our “Patient First” operating principle will remain central to our operations, engaging our employees and aligning our efforts with your missions. This commitment is unwavering.
Sincerely,
Alessandro Maselli
President and Chief Executive Officer, Catalent
Catalent’s acquisition by Novo Holdings is anticipated to close towards the end of 2024, subject to standard closing conditions, including regulatory approvals. This transaction does not hinge on any financing contingencies.
ABOUT CATALENT
Catalent, Inc. (NYSE: CTLT), is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner development programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply nearly 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 17,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated approximately $4.4 billion in revenue in its 2024 fiscal year.
